Lymphoma & Myeloma 2008

 
 
 

Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies took place October 16-18, 2008, in New York, New York. The meeting was chaired by Morton Coleman, MD; John P. Leonard, MD; Ruben Niesvizky, MD; and Richard R. Furman, MD, all from Weill Cornell Medical College.

 

Treating the bone disease of multiple myeloma

Erilyn Riley Read Article
Published: 10/31/08

Multiple myeloma patients experience a 6 times greater incidence of bone fracture compared to healthy individuals. And as life expectancy for multiple myeloma patients increases, so does the need to treat their bone disease. Experts at Lymphoma & Myeloma 2008 discussed treatment strategies, including the pros and cons of bisphosphonates. James R. Berenson, MD, of the Institute for Myeloma and Bone Cancer Research in Los Angeles, emphasized the prognostic significance of skeletal-related events (SREs) for MM patients. Suzanne Lentzsch, MD, PhD, of the University of Pittsburgh, described the basic science of osteolytic bone disease and potential strategies for treatment in MM. [Read Article]

New strategies, agents may turn indolent lymphoma into chronic disease

Mark Fuerst Read Article
Published: 10/29/08

There is no standard of care for generally incurable indolent B-cell lymphomas, but survival is improving with newer treatment modalities, according to a presentation at Lymphoma & Myeloma 2008. Stephanie Gregory, MD, of Rush University Medical Center in Chicago, said the goal of therapy is to make these lymphomas chronic diseases that can be treated with relatively nontoxic approaches. And there are many emerging novel agents that hold promise, including monoclonal antibodies and radioimmunotherapy. Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies took place October 16-18. [Read Article]

Keynoter hails progress in treating MM

Mark Fuerst Read Article
Published: 10/27/08

Bart Barlogie, MD
Bart Barlogie, MD

The addition of novel agents to recent Total Therapy (TT) protocols has markedly improved complete remissions and survival in multiple myeloma, according to the keynote speaker at Lymphoma & Myeloma 2008. Bart Barlogie, MD, updated results from TT trials to reflect the inclusion of thalidomide and bortezomib. The TT protocol, devised at the University of Arkansas in 1989, calls for clinicians to apply all active treatment ingredients upfront in newly diagnosed multiple myeloma patients. [Read Article]

Presenter predicts improvements in multiple myeloma therapy

Mark Fuerst Read Article
Published: 10/24/08

Kenneth Anderson, MD
Kenneth Anderson, MD

The next 5 years will be even better than the last 5 years, in terms of designing optimal combined therapies for multiple myeloma, according to a speaker at Lymphoma & Myeloma 2008. Kenneth Anderson, MD, of the Dana-Farber Cancer Institute, discussed a handful of promising novel targeted therapies in multiple myeloma, including carfilzomib, HuLuc63, and AZD6244. He also predicted the next drug to win FDA approval would be the heat shock protein 90 inhibitor tanespimycin. [Read Article]

Some FL patients may safely defer treatment

Mark Fuerst Read Article
Published: 10/24/08

Though the common practice in oncology is to treat all patients, this approach should not be used in follicular lymphoma, according to a presenter at Lymphoma & Myeloma 2008. Brian Link, MD, of the University of Iowa, pointed out that treating all patients is commonplace with cancer of the breast, colon, and lung. In those settings, data from randomized studies demonstrates a survival advantage, but similar data does not exist for patients with follicular lymphoma. [Read Article]

Rituximab insufficient treatment for DLBCL

Jen Smith Read Article
Published: 10/23/08

Though rituximab has been hailed for changing the natural history of lymphoma, the drug is not effective enough in DLBCL, according to a speaker at Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies. Thomas M. Habermann, MD, of the Mayo Clinic, acknowledged that rituximab greatly improves the efficacy of CHOP. However, the combination does not allow for prolonged survival in a majority of DLBCL patients. Clinicians should therefore explore other avenues— such as novel anti-CD20 monoclonal antibodies, radioimmunotherapy, and agents capable of inhibiting newly found targets— to treat DLBCL. [Read Article]

Cell cycle control and multiple myeloma

Frieda Pearce, PhD Read Article
Published: 10/19/08

The first mouse model of multiple myeloma (MM) to recapitulate human disease was presented at Lymphoma & Myeloma 2008. According to presenter P. Lief Bergsagel, MD, FRCP, of Mayo Clinic Arizona, this model will be useful in preclinical evaluation of new agents, in determining treatment efficacy and schedules, and in studying molecular aspects of MM. [Read Article]

Treating primary CNS lymphoma

Frieda Pearce, PhD Read Article
Published: 10/18/08

The treatment approach for primary CNS lymphoma is not well-defined because there are still many unanswered questions, according to a speaker at Lymphoma & Myeloma 2008. Lauren E. Abrey, MD, from the Memorial Sloan-Kettering Cancer Center, discussed this dilemma in detail at the conference, which took place October 16-18 in New York, NY. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}